Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glioma × rindopepimut × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Neoplasms 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Brain Neoplasms 1

Interventions

Temozolomide 59 Bevacizumab 37 Radiotherapy 19 Magnetic Resonance Spectroscopy 18 Irinotecan 16 Carboplatin 10 Specimen Handling 9 Carmustine 9 olaparib 6 X-Rays 6 Surgical Procedures, Operative 6 Phantoms, Imaging 6 Cyclophosphamide 6 Thalidomide 5 Nuclear Medicine Department, Hospital 5 Nivolumab 5 Biopsy 5 trametinib 4 pembrolizumab 4 Radiation 4 Lomustine 4 Everolimus 4 Cisplatin 4 Aminolevulinic Acid 4 sargramostim 3 poly ICLC 3 palbociclib 3 ivosidenib 3 fluorodopa F 18 3 erdafitinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00458601 2018-01-16

ACT III

Celldex Therapeutics

Phase 2 Completed

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡